PR Newswire/Les Echos/
Sanofi Hosts French President François Hollande at Facility in South Africa
- French Leader visits antituberculosis and antiretroviral drugs manu facturing
plant based in Waltloo, Pretoria -
Paris, France and Pretoria, South Africa - October 15, 2013 - French President
François Hollande today visited Sanofi's Waltloo industrial manufacturing plant
in Pretoria, South Africa, accompanied by a delegation of ministers, members of
Parliament and business leaders.
The Waltloo facility produces and distributes tuberculosis (TB) and HIV/AIDS
treatments for South Africa and exports antituberculosis drugs to Sub Saharan
Africa, Europe, South America, Thailand, Middle East and Australia.
"We are very honored by this visit which demonstrates the support of President
Hollande and his administration for our industry," said Philippe Luscan,
Excecutive Vice President, Global Industrial Affairs, Sanofi. "By making Waltloo
a world center in the fight against two epidemic diseases, namely tuberculosis
and HIV/A IDS, in one of the countries most affected by these, Sanofi is
demonstrating our strong commitment to South Africa and addressing important
public health priorities."
In 2012, Sanofi signed an agreement to partner with Hetero for an antiretroviral
(ARV) product portfolio manufactured locally by Sanofi. The objective is to
deliver quality ARV products at affordable prices and increase the manufacturing
offer for ARV products in South Africa. These initiatives are aligned to the
government's National Industrial Policy, where the pharmaceutical industry has
been identified as a strategic sector for economic growth. The expansion at the
Waltloo facility has allowed Sanofi to retain and create new employment
opportunities, through skills development initiatives and skills transfer
Over the past seven years, Sanofi successfully implemented the TB FREE project
in partnership with the Min istry of Health of South Africa through a donation
of EUR 15 million by Sanofi. The TB FREE initiative supported the Department of
Heath's TB Control Program by training over 55,000 Directly Observed Treatment
(DOT) supporters who assist TB patients to ensure adherence and completion of
their TB treatment, TB education and awareness campaigns. The second phase of
the project was launched in 2012 under the name INHIBIT TB, a program to screen
family contacts of people diagnosed with TB in their homes. This project
involves care workers going to the homes of TB patients and offering family mem
bers an opportunity to be screened for TB and HIV.
Sanofi has been present in South Africa for more than 50 years and has a
workforce of approximately 800 people, including 260 at the Waltloo site.
Sanofi, an integrated global healthcare leader, discovers, develops and
distributes therapeutic solutions focused on patients' needs. Sanofi has core
strengths in the field of healthcare with seven growth platforms: diabetes
solutions, human vaccines, innovative drugs, consumer healthcare, emerging
markets, animal health and the new Genzyme. Sanofi is listed in Paris
(EURONEXT: SAN) and in New York (NYSE: SNY).
Relations Presse Relations Investisseurs
Laurence Bollack Sébastien Martel
Tel +33 (1) 53 77 46 46 Tel +33 (1) 53 77 45 45
The content and accuracy of news releases published on this site and/or
distributed by PR Newswire or its partners are the sole responsibility of the
originating company or organisation. Whilst every effort is made to ensure the
accuracy of our services, such releases are not actively monitored or reviewed
by PR Newswire or its partners and under no circumstances shall PR Newswire or
its partners be liable for any loss or damage resulting from the use of such
information. All information should be checked prior to publication.
-0- Oct/15/2013 09:18 GMT
Press spacebar to pause and continue. Press esc to stop.